Safety and Efficacy of Meplazumab in Patients With Coronary Artery Disease

Inclusion criteria

• Patients with chronic coronary syndrome
• Non-target lesions with stenosis ≥50% by visual assessment
• Angina symptoms manageable via antianginal medication
• High attenuation coefficient (≥-70.1 HU) of perivascular adipose tissue (PVAT) around non-target lesions as assessed by coronary CT angiography (CCTA)
• Patients who are able to complete the follow-up and compliant to the prescribed medication

Exclusion criteria

• Under the age of 18
• Unable to give informed consent or currently participating in another trial and not yet at its primary endpoint
• Patient is a woman who is pregnant or nursing (a pregnancy test must be performed within 7 days prior to the index procedure in women of child-bearing potential according to local practice)
• Concurrent medical condition with a life expectancy of less than 3 years
• Haemodynamical unstable
• Known contraindications to medications such as test drug and its components, heparin, or contrast
• The following criteria are met for any of the laboratory test indicators at the time of screening ①ALT/AST >3ULN；②TBil ≥2ULN；③WBC>2ULN；④NEUT<0.5×109 /L；⑤PLT<30×109 /L；⑥eGFR &amp;lt;60 mL/min/1.73 m2（CKD-EPI formula）
• Suffering from severe systemic diseases, tumors, immune system disorders, infections, malignancy, which in the opinion of the investigator make participation in this study inappropriate